India Generic Drugmaker Natco Brings Patent Challenge-Style to U.S.

Apr 09, 2015


Hyderabad-based Natco Pharma, best known for challenging drug patents in India, has filed 11 applications with the U.S. FDA to market generic drugs before their U.S. patents expire.

Natco, looking to be among the first to win approval for its generic version of Teva's Copaxone, is also looking to market generics for big-ticket drugs such as Celgene Corp.’s Revlimid for bone cancer and Roche’s Tamiflu.

Currently, Natco derives only a seventh of its annual revenue from U.S. drug sales. According to the company, their new goal is to file eight to 10 generic drug applications per year in the U.S.

Read the Bloomberg article

Show Comments
Hide Comments

Join the discussion

We welcome your thoughtful comments.
All comments will display your user name.

Want to participate in the discussion?

Register for free

Log in for complete access.


No one has commented on this page yet.

RSS feed for comments on this page | RSS feed for all comments